Antibody Ingredients TRIZ Cases

Combining anti-HER-3 antibody with radiation therapy overcomes insufficient radiosensitivity of tumor cells through synergistic DNA damage and apoptosis.

Antibodies bind BCL-6 protein to inhibit endothelial cell proliferation, countering tumor evasion of VEGF-targeting therapies.

Extracting the VHH domain reduces molecular weight and immunogenicity while improving tissue penetration.

Engineered antibodies bind specifically to the KRS N-terminal epitope, resolving cross-reactivity issues and inhibiting cancer metastasis.

Combines an RNA vaccine encoding tumor antigens with a PD-1 pathway inhibitor to stimulate targeted immune responses.

Avelumab aqueous formulation eliminates methionine antioxidants while maintaining stability at pH 5.2 through optimized buffering and surfactant systems.

A blood-based test kit measures VEGF-A and VEGF-D concentrations to predict therapeutic efficacy of anti-VEGFR-2 antibody drugs.

Monoclonal antibodies bind human hepcidin-25 to neutralize bioactivity and increase red blood cell production.

Novel HER2 antibody 1E11 targets distinct epitopes to enhance cytotoxicity against breast and stomach cancers resistant to trastuzumab.

Antibodies targeting conserved hemagglutinin regions neutralize diverse influenza A subtypes, overcoming antigenic drift limitations.

Antibodies targeting 4-1BB and LAG-3 restore dysfunctional CD8+ T cell function in the tumor microenvironment.

Isolated anti-CD30 antibody lacking fucosyl and xylosyl residues enhances antibody-dependent cellular cytotoxicity.

Als3 polypeptide antibodies overcome drug resistance by inducing immune responses that reduce Candida auris burden.

High affinity monoclonal antibody resolves dose trade-offs by inhibiting tumor growth at low concentrations across multiple cancer types.

Novel PD-1 antibodies employ targeted CDR modifications to resolve the trade-off between high-affinity human blocking and cross-species murine compatibility.

pH-sensitive mutant anti-CTLA-4 antibodies bind at neutral pH and dissociate in acidic environments to preserve agonist activity.

Combining anti-CD5 and anti-HLA-DR antibodies extends survival in lymphoma models by overcoming limited efficacy of single-agent treatments.

SEMA7A monoclonal antibodies target Semaphorin 7A expression to reduce tumor growth and metastasis in estrogen receptor positive breast cancers.

Merges CTLA-4 and PD-1 antibodies to overcome single-agent limitations and boost immune response.

Engineered antibodies target the peptide-MHC interface to reduce off-target cross-reactivity while maintaining killing efficacy.

Multi-parameter flow cytometry measures PD-1 and CTLA-4 expression on leukocytes to identify specific immune phenotypes associated with cancer treatment response.

A recombinant adenovirus vector vaccine encodes HER3 antigens to stimulate robust immune responses.

BCMA-PD-1 antibody combination breaks immune tolerance by inducing immunogenic cell death and activating dendritic cells.

Targeting the alpha5-helix of HIV gp120 elicits broad neutralizing antibodies that prevent viral reversion and ensure protective immunity.

Antagonistic TNFR2 antibodies block regulatory T cell proliferation to expand tumor-reactive effector populations.

Dual checkpoint inhibition with optimized tremelimumab and durvalumab dosing improves overall survival in advanced hepatocellular carcinoma.

Cysteine residues at positions 80 and 171 create disulfide bonds that boost thermal stability without compromising antigen binding affinity.

Multispecific antigen-binding molecules link RNF43-expressing cancer cells to T cell receptors, inducing cytotoxicity while avoiding cytokine storms.

Merges CSF1R inhibition with CD40 stimulation to deplete suppressive macrophages and activate T cells, overcoming single-agent limitations.

Engineered anti-FLT3 antibodies stimulate dendritic cell activity through targeted Fc region mutations.

Segmented therapeutic compounds link targeting domains to inhibiting domains via a linker structure.

Segmented minibody and cys-diabody formats reduce clearance time and immune response while improving diagnostic accuracy for prostate cancer.

Selective EP4 receptor antagonists block PGE2-mediated signaling to disrupt the immunosuppressive tumor microenvironment and enhance immune response.

Anti-SSTR2 antibody-drug conjugates target somatostatin receptors on neuroendocrine cancer cells, reducing systemic toxicities from traditional chemotherapy.

Genetically engineered mice produce high-affinity IgG antibodies targeting 3',6'-isoLD1 gangliosides, reducing non-specific binding to other gangliosides.

A Fab-scFv fusion protein binds tumor antigens and cytotoxic lymphocyte receptors to engage effector cells.

Engineered antigen-binding protein constructs utilize pH-responsive dissociation kinetics to enhance intracellular toxin delivery.

FcγRIIB-specific antibodies bind receptors with high affinity to modulate immune responses, addressing therapy resistance and side effects in cancer treatment.

Patient-specific neoplasia vaccines paired with checkpoint inhibitors overcome self-tolerance and immune suppression to enhance anti-tumor efficacy.

Anifrolumab targets the interferon-alpha receptor to suppress disease activity while avoiding broad immunosuppression side effects.

A multi-analyte biomarker measurement method evaluates lung cancer treatment efficacy using standardized assays.

A trispecific binding protein engages CD38, CD28, and CD3 to activate antigen-specific T cells.

TIGIT-binding agents block ligand interactions to resolve cancer cell evasion and boost cytolytic activity.

Anti-beta klotho antibodies activate the beta klotho/FGF receptor complex to induce metabolic signaling pathways.

A pharmaceutical composition comprising an anti-PD-1 antibody formulated with acetate buffer at pH 4.5 to 6.0.

Specific ACKR2 modulators block CXCL10 and CCL5 scavenging, increasing chemokine bioavailability to convert cold tumors to hot microenvironments.

CFZ533 antibody inhibits CD40-CD154 signaling, preventing graft rejection while avoiding thromboembolic events associated with anti-CD154 agents.

Sequential radiotherapy combines high and low dose radiation to disrupt tumor stroma, enabling immune cell penetration into secondary sites.